Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology.
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
The quantification of phosphorylated tau in biofluids, either cerebrospinal fluid (CSF) or plasma, has shown great promise in detecting Alzheimer’s disease (AD) pathophysiology. Tau phosphorylated at threonine 231 (p-tau231) is one such biomarker in CSF but its usefulness as a blood biomarker is currently unknown. Here, we developed an ultrasensitive Single molecule array (Simoa) for the quantification of plasma p-tau231 which was validated in four independent cohorts ( n = 588) in different settings, including the full AD continuum and non-AD neurodegenerative disorders. Plasma p-tau231 was able to identify patients with AD and differentiate them from amyloid-β negative cognitively unimpaired (CU) older adults with high accuracy (AUC = 0.92–0.94). Plasma p-tau231 also distinguished AD patients from patients with non-AD neurodegenerative disorders (AUC = 0.93), as well as from amyloid-β negative MCI patients (AUC = 0.89). In a neuropathology cohort, plasma p-tau231 in samples taken on avergae 4.2 years prior to post-mortem very accurately identified AD neuropathology in comparison to non-AD neurodegenerative disorders (AUC = 0.99), this is despite all patients being given an AD dementia diagnosis during life. Plasma p-tau231 was highly correlated with CSF p-tau231, tau pathology as assessed by [ 18 F]MK-6240 positron emission tomography (PET), and brain amyloidosis by [ 18 F]AZD469 PET. Remarkably, the inflection point of plasma p-tau231, increasing as a function of continuous [ 18 F]AZD469 amyloid-β PET standardized uptake value ratio, was shown to be earlier than standard thresholds of amyloid-β PET positivity and the increase of plasma p-tau181. Furthermore, plasma p-tau231 was significantly increased in amyloid-β PET quartiles 2–4, whereas CSF p-tau217 and plasma p-tau181 increased only at quartiles 3–4 and 4, respectively. Finally, plasma p-tau231 differentiated individuals across the entire Braak stage spectrum, including Braak staging from Braak 0 through Braak I–II, which was not observed for plasma p-tau181. To conclude, this novel plasma p-tau231 assay identifies the clinical stages of AD and neuropathology equally well as plasma p-tau181, but increases earlier, already with subtle amyloid-β deposition, prior to the threshold for amyloid-β PET positivity has been attained, and also in response to early brain tau deposition. Thus, plasma p-tau231 is a promising novel biomarker of emerging AD pathology with the potential to facilitate clinical trials to identify vulnerable populations below PET threshold of amyloid-β positivity or apparent entorhinal tau deposition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Plasma p-tau231 concentration correlates with PET and CSF tau and Aβ. The brain maps show the results of linear regressions false discovery rate corrected for multiple comparisons at P < 0.05, whereas the plots show the results of Spearman rank correlation between biomarkers. a Plasma p-tau231 concentrations were associated with [18F]MK-6240 SUVR across the cortex with the highest association in the temporal and posterior cingulate cortices as well as with b CSF p-tau231 concentrations. c Plasma p-tau231 correlates with [18F]AZD4694 SUVR across the cortex and with d CSF Aβ1-42 concentrations](https://figures.cochat.ai/paper-figures/11450d600b6547cd8ddd582223ba6f57/plasma-p-tau231-a-new-biomarker-for-incipient-alzheimers-disease-pathology-figure-2.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Among proposed blood tau biomarkers,18,19,20,21 phosphorylated tau at threonine 217 (p-tau217) has consistently shown high performance in differentiating AD from other neurodegenerative disorders10,22 and in detecting AD pathology in patients with mild cognitive impairment (MCI).22”
From Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology (2024) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“The new plasma p-tau231 Simoa assay has been previously described and validated2.”
From Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease (2022) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Plasma measures of phosphorylated tau at Thr181 (p-tau181), Thr217 (p-tau217) and Thr231 (p-tau231) have high diagnostic accuracy in differentiating AD from other neurodegenerative disorders in clinical studies1–3, which are validated by postmortem neuropathological studies1,2,4.”
From Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease (2022) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Subsequently, the first blood analysis of p-tau231 (ref. 2) demonstrated earlier increases than plasma p-tau181 in a small set of participants.”
From Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease (2022) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“P-tau231 levels in blood have also recently been demonstrated to increase earlier than p-tau18160 (Tissot et al., 2022), however, a direct comparison with p-tau217 in early preclinical disease is not currently available.”
From Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease (2022) · cites this paper as [60]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Robust Locally Weighted Regression and Smoothing Scatterplots
Cleveland, W. S. (1979) · Journal of the American Statistical Association · doi:10.1080/01621459.1979.10481038 · Cited by 11,594
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Self-citationHigh performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603
Self-citationThe Centiloid Project: standardizing quantitative amyloid plaque estimation by PET
Klunk, W. E., Koeppe, R. A., Price, J. C., Benzinger, T. L., Devous, M. D., Jagust, W. J., Johnson, K. A., Mathis, C. A., Minhas, D., Pontecorvo, M. J., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.07.003 · Cited by 1,348
Cited by
Items 501–600 of 769
Tatar, A.-S., Colniță, A., Brezeștean, I.-A., & Boca, S. (2026) · Biophysical Reviews · doi:10.1007/s12551-026-01428-9 · Cited by 3
Zafari, R., Kamroo, A., Taherkhani, T., Nabizdeh, F., & Aarabi, M. H. (2026) · Neuroscience · doi:10.1016/j.neuroscience.2026.05.010 · Cited by 3
Detecting amyloid–β pathology in subjective cognitive decline using plasma and CSF biomarkers
Contador, J., Pozzi, F. E., Sánchez‐Benavides, G., Fernández‐Arcos, A., Lantero‐Rodriguez, J., Montoliu‐Gaya, L., Minguillón, C., Fauria, K., González‐Escalante, A., Ortiz‐Romero, P., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106331 · Cited by 3
Self-citationZaman, W., Ayaz, A., & Ullah, A. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118275 · Cited by 3
Plasma biomarkers of amyloid, tau, astrogliosis, and axonal injury in a mixed memory clinic cohort
Gleerup, H. S., Simonsen, A. H., Grötschel, L., Gramkow, M. H., Høgh, P., Blennow, K., Zetterberg, H., Ashton, N. J., & Hasselbalch, S. G. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70073 · Cited by 3
Self-citationBruno, D., Plaska, C. R., Zinkunegi, A. J., Ashton, N. J., Zetterberg, H., Blennow, K., & Pomara, N. (2025) · Journal of Neuropsychology · doi:10.1111/jnp.70012 · Cited by 3
Self-citationCao, T. H. M., Le, A. P. H., Tran, T. T., Huynh, V. K., Pham, B. H., Le, T., Nguyen, Q. L., Tran, T. C., Tong, T. M., Than, T. H. N., et al. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1308610 · Cited by 3
New Research on Biomarkers in Alzheimer’s Continuum
Vecchio, I., & Colica, C. (2025) · Reviews on Recent Clinical Trials · doi:10.2174/0115748871331138250114052615 · Cited by 3
Carrasco-Gómez, M., García‐Colomo, A., Nebreda, A., Bruña, R., Santos, A., & Maestú, F. (2025) · Clinical Neurophysiology · doi:10.1016/j.clinph.2025.2110751 · Cited by 3
Tanaka, M. T., Tanji, K., Miki, Y., Ozaki, T., Mori, F., Hayashi, H., Kakita, A., & Wakabayashi, K. (2022) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlac082 · Cited by 3
An investigation into Alzheimer's disease, its current treatments, biomarkers, and risk factors
Srivastav, A. P. Y., Prajapati, A., Prajapati, A., Kumar, M., & Siddiqui, M. A. (2023) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.55948/ijerste.2023.0722 · Cited by 3
Tavares-Júnior, J. W. L., Ciurleo, G. C. V., Feitosa, E. D. A. A. F., Oriá, R. B., & Braga‐Neto, P. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231368 · Cited by 3
Yakoub, Y., Qiu, T., Peyrot, C., Salvadó, G., Villeneuve, S., Binette, A. P., & Initiative, A. D. N. (2025) · medRxiv · doi:10.1101/2025.09.30.25337003 · Cited by 3
A novel pThr217 tau monoclonal antibody reveals neuropathological heterogeneity in tauopathies
Paterno, G., Bell, B. M., Gorion, K.-M. M., Quintin, S. S., Prokop, S., & Giasson, B. I. (2025) · Scientific Reports · doi:10.1038/s41598-025-04291-y · Cited by 2
Malotaux, V., Ashton, N. J., Öhrfelt, A., Chen, Y., Su, Y., Garcia‐Ospina, G., Guzman‐Martínez, C., Villegas‐Lanau, A., Gómez‐Ramirez, J., Giraldo, M., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70421 · Cited by 2
Self-citationApplication of protein misfolding amplification techniques in prion diseases
Liu, R., Chen, Z., Wang, Y., & Wu, L. (2025) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2025.18 · Cited by 2
Unlocking the Future of Alzheimer's Disease: Innovations in Diagnosis and Therapy
Mehndiratta, M. M., Singla, M., & Dixit, A. (2025) · Journal of the Association of Physicians of India · doi:10.59556/japi.73.1075 · Cited by 2
Molecular pathways and biomarkers associated with age-related cognitive decline
Mitra, S., Pandey, S., Gill, A., Roy, A., Dutta, S., Kumar, A., Ali, M., & Chawla, G. (2025) · Academia Biology · doi:10.20935/acadbiol7909 · Cited by 2
Vijiaratnam, N., Girges, C., Mitchell, A., Athauda, D. S., Fumi, R., Hay, J., O’Reilly, N., Morris, H. R., Carroll, C., Hu, M., et al. (2026) · Brain Communications · doi:10.1093/braincomms/fcag035 · Cited by 2
Vascular stiffness predicts plasma markers of neurodegeneration among older African Americans
Budak, M., Heffernan, K. S., Paruzel, V., Moallemian, S., Fausto, B. A., Ashton, N. J., Zetterberg, H., Elahi, F. M., & Gluck, M. A. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100523 · Cited by 2
Self-citationTau pathology in epilepsy: emerging mechanisms and translational opportunities
Sen, A., Tai, X. Y., Galanopoulou, A. S., Thom, M., Aronica, E., Vivash, L. E., Hardmeier, M., Amos, A., Rüegg, S. J., Koepp, M. J., et al. (2026) · Brain · doi:10.1093/brain/awag108 · Cited by 2
Yakubu, A. O., Atafo, G. I., Nwaze, C. E., Bakare, T. Y., Adeniyi, T. O., Alare, K., Oladele, A. B., & Solagbade, O. S. (2026) · NeuroMarkers. · doi:10.1016/j.neumar.2026.100167 · Cited by 2
Presymptomatic plasma biomarkers in autosomal dominant Alzheimer’s disease: sequence and timing
Belder, C. R. S., Heslegrave, A., Swann, O., Abel, E., Beament, M., Nasir, M., Rice, H., Weston, P. S. J., Ryan, N. S., Palmer, L. J., et al. (2026) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2026-339037 · Cited by 2
Self-citationQi, J., Li, L. J., Duan, H., Sun, Y., & Zhang, J. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1801239 · Cited by 2
Martínez-Bujidos, M., Menéndez, A., Pulido-Gracia, J. A., Vilas, D., Samaniego, D., Ispierto, L., Morales‐Indiano, C., & Pástor, P. (2026) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2026-0395 · Cited by 2
Chen, X., Huang, T., Shi, C., Xu, S., & Fan, S. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1834591 · Cited by 2
Chai, L., Zhan, Y., Huang, Y., Tian, M., Zhao, G., Ni, J., Xiong, X., Huang, J., & Lin, B. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02104-6 · Cited by 2
Yang, K. L., Ma, Y., Ennis, G. E., Jonaitis, E., Reyes, R. E. R., Johnson, S. C., Ashton, N. J., Blennow, K., Zetterberg, H., & Bendlin, B. B. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70383 · Cited by 2
Self-citationDiagnosis and management of frontotemporal dementia: a narrative review
Cenacchi, V., Lombardo, T., Palacino, F., Cattaruzza, T., Manganotti, P., & Benussi, A. (2026) · Neurodegenerative Disease Management · doi:10.1080/17582024.2026.2687481 · Cited by 2
Mohammed, H. E., Haseeb, M. E., Nasser, M., Hanen, G., Abdelkader, M., Yaser, H., Yaser, S., Samir, A., Arafeh, Y., Wagdy, M., et al. (2026) · Acta Neurologica Belgica · doi:10.1007/s13760-026-03107-8 · Cited by 2
CSF and plasma tau biomarkers in the Down syndrome–Alzheimer’s disease continuum
Arranz, J., Lantero‐Rodriguez, J., Braun-Wohlfahrt, L. S., Vaqué‐Alcázar, L., Rodríguez‐Baz, Í., Kac, P. R., Arslan, B., Maure‐Blesa, L., Pertierra, L., Videla, L., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106370 · Cited by 2
Self-citationProminent Perspective on Existing Biological Hallmarks of Alzheimer’s Disease
Singh, N., Sharma, S., Ghosh, K. K., Gupta, B., & Kuča, K. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266292514240404040341 · Cited by 2
Biomarkers and Alzheimer’s Disease: What Will the Future Bring for ‘The Worried Well’?
Fornazzari, L., & Fischer, C. E. (2021) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2021.126 · Cited by 2
Yeast biopanning against site-specific phosphorylations in tau
Arbaciauskaite, M., Pirhanov, A., Ammermann, E. J., Yu, L., & Cho, Y. K. (2023) · Protein Engineering Design and Selection · doi:10.1093/protein/gzad005 · Cited by 2
Miller, J. S., Rose, M. R., Roell, J., Ubhe, S., Liu, T., Segal, B. M., & Bell, E. H. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1473917 · Cited by 2
Biomarkers for Neurodegenerative Diseases
Abdelmoaty, M. M., Lu, E., & Foster, E. G. (2024) · Springer eBooks · doi:10.1007/978-3-031-68237-7_44 · Cited by 2
Zeng, A., Shuai, Z., Pan, D., & Lin, J. (2025) · Europe PMC (PubMed Central) · doi:10.7507/1001-5515.202405035 · Cited by 2
Xu, Q., Zhang, H., Ruan, N., Jing, J., Li, Y., Zhao, J., & Fang, Z. (2025) · ACS Omega · doi:10.1021/acsomega.4c09662 · Cited by 2
Hou, L., Xin, L., Liu, Y., He, B., Shi, C., & Yang, Y. (2025) · Behavioural Brain Research · doi:10.1016/j.bbr.2025.115711 · Cited by 2
Neurodegeneration: 2021 update
Crary, J. F. (2021) · Free Neuropathology · doi:10.17879/freeneuropathology-2021-3317 · Cited by 2
Wang, S., Jiang, S., Zheng, G., & Cho, Y. K. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.01.506229 · Cited by 2
Rumo a uma nova era no diagnóstico e tratamento da doença de Alzheimer
Ferrari‐Souza, J. P., & Schilling, L. P. (2023) · PAJAR - Pan-American Journal of Aging Research · doi:10.15448/2357-9641.2023.1.44542 · Cited by 2
Impact of clinical severity on plasma p-tau performance in predementia Alzheimer’s diseasePreprint
González‐Ortiz, F., Kirsebom, B., Yakoub, Y., Gundersen, J. K., Pålhaugen, L., Waterloo, K. K., Selnes, P., Jarholm, J. A., Gísladóttir, B., Rongve, A., et al. (2024) · medRxiv · doi:10.1101/2024.08.06.24311532 · Cited by 2
Self-citationTrajectories of blood-based protein biomarkers in chronic traumatic brain injuryPreprint
Hicks, A. J., Plourde, J., Selmanovic, E., de Souza, N. L., Blennow, K., Zetterberg, H., & Dams-O’Connor, K. (2025) · medRxiv · doi:10.1101/2025.02.16.25322303 · Cited by 2
Self-citationClinicopathological and prognostic correlations of plasma biomarkers in neurodegenerative diseasesPreprint
Malpetti, M., Chouliaras, L., Murley, A. G., Swann, P., Coyle-Gilchrist, I. T. S., Bevan-Jones, W. R., Savulich, G., Perquin, M. N., Wiggins, J., Bowns, L., et al. (2025) · medRxiv · doi:10.64898/2025.12.07.25341788 · Cited by 2
Self-citationTau pathological binding activity in plasma before the onset of symptomatic Alzheimer’s diseasePreprint
Hanseeuw, B. J., Quenon, L., Bayart, J., Boyer, E., Colmant, L., Salman, Y., Gérard, T., Huyghe, L., Malotaux, V., Kienlen‐Campard, P., et al. (2026) · medRxiv · doi:10.64898/2026.04.03.26350110 · Cited by 2
Development of Fluid Biomarkers for Alzheimer’s Disease
Blennow, K. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108975759.033 · Cited by 1
Self-citationZhen, W., Wang, Y., Zhen, H., Zhang, W., Shao, W., Sun, Y., Qiao, Y., Jia, S., Zhou, Z., Wang, Y., et al. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1513930 · Cited by 1
Research Progress on Alzheimer's Disease Biomarkers Based on the ATX(N) Framework
Cao, H., Zhang, W., Lin, J., & Yu, E. (2025) · Discovery Medicine · doi:10.24976/discov.med.202537193.21 · Cited by 1
Blood biomarkers of Alzheimer’s disease: findings from proteomics
Wang, Y., Niu, X., Zhen, W., Zhang, B., Chen, L., Liu, Y., Sun, W., & Peng, D. (2025) · Postgraduate Medical Journal · doi:10.1093/postmj/qgaf039 · Cited by 1
Anti-amyloid Monoclonal Antibodies for Alzheimer’s Disease: A New Hope? (Review)
Мазеркина, И. А. (2025) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2025-13-1-7-19 · Cited by 1
Agostini, M., Traldi, P., & Hamdan, M. H. (2025) · NeuroSci · doi:10.3390/neurosci6020050 · Cited by 1
BIOCHEMICAL MARKERS FOR EARLY DETECTION OF DEMENTIA: A REVIEW OF CURRENT ADVANCES
Cabrini, G. B., Schoen, P., Consolo, E. D., & Gonçalves, C. (2025) · Asclepius International Journal of Scientific Health Science · doi:10.70779/aijshs.v4i6.142 · Cited by 1
Choroidal evaluation of FTLD-Tau and biomarker-determined Alzheimer’s disease
Kim, B. J., Alemán, T. S., Cousins, K. A. Q., Daniel, E., Smith, E. J., Iacobucci, E., Kolomeyer, A. M., Hwang, C. K., McMillan, C. T., Deerlin, V. M. V., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-02020-z · Cited by 1
Rich, A., Oh, H., & Initiative, A. D. N. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251361354 · Cited by 1
Maphis, N. M., Furlano, D. A., David, S. A., & Linsenbardt, D. N. (2025) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.70123 · Cited by 1
Tauopathy strains differentially replicate in vitro in the presence of mutant tau monomer
Brown, C. K., Frost, M. P., Holec, S. A. M., Seeley, W. W., Grinberg, L. T., Olson, S. H., & Woerman, A. L. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107052 · Cited by 1
Bolton, C. J., Zhang, P., Nair, D., Liu, D., Davis, L. T., Pechman, K. R., Shashikumar, N., Wilhoite, S., Roby, D., Beeson, C., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70651 · Cited by 1
Self-citationLithium mitigates hippocampal tau pathology in a rodent model of traumatic brain injury
Donison, N. S., Palik, J., Hintermayer, M. A., Volkening, K., & Strong, M. J. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02170-1 · Cited by 1
Investigating Microtubule-Associated Protein 2 in the Study of Postoperative Delirium
McKay, T. B., Graves, O. K., Toombs, A., Simon, C., & Akeju, O. (2026) · Delirium · doi:10.56392/001c.155608 · Cited by 1
Pashaei, S., Mirzaei, S. Z., Mohammadi, S., Shabani, S., & Khodarahmi, R. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.150648 · Cited by 1
Delaby, C., & Lehmann, S. (2026) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2025-1731 · Cited by 1
Fernandes, M. G. F., Pinard, M., Sokullu, E., Tremblay, C., Gagnon, J., Calon, F., Coulombe, B., & Brouillette, J. (2026) · The Journals of Gerontology Series A · doi:10.1093/gerona/glag009 · Cited by 1
Rao, A. R., Pradhan, R., Anwar, M., Gupta, A., Bhagwasia, M., Nichols, E., Gross, A. L., Thyagarajan, B., Hu, P., Crimmins, E. M., et al. (2026) · Journal of the American Geriatrics Society · doi:10.1111/jgs.70336 · Cited by 1
Xie, Y., Cai, W., Zhao, X., & Li, R. (2026) · Organ medicine. · doi:10.1002/orm2.70032 · Cited by 1
Association of plasma glial fibrillary acidic protein and APOE-ε4 with Alzheimer’s disease
Zhu, Y., Lan, G., Li, A., Zhang, L., Jiang, M., Yang, J., Zhu, J., He, Z., Xin, Z. H. O. U., Li, M., et al. (2026) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2026.03.009 · Cited by 1
Zhang, R., Dong, X., Pei, G., & Huang, S. (2026) · Neuroscience Bulletin · doi:10.1007/s12264-026-01615-4 · Cited by 1
Groh, J. R., Miner, A. E., Alshikho, M. J., Farris, C. W., Cui, A., Pettway, E. C., Labonte, J., Mosaheb, S., Tripodis, Y., Adler, C. H., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71351 · Cited by 1
Self-citationDelaby, C., & Lehmann, S. (2026) · Laboratory Service · doi:10.17116/labs20261502137 · Cited by 1
Gaetani, L., Nardi, G., & Parnetti, L. (2026) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2026.2700246 · Cited by 1
Li, C., Cheng, T., & Lin, C. Y. (2026) · npj Parkinson s Disease · doi:10.1038/s41531-026-01469-7 · Cited by 1
Plasma Phosphorylated Tau 217 in Participants at Risk for Chronic Traumatic Encephalopathy
Miner, A. E., Zetterberg, H., Blennow, K., Groh, J. R., Singh, A., Dieckhoff, K., Tripodis, Y., Adler, C. H., Balcer, L. J., Bernick, C. B., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.22966 · Cited by 2
Self-citationNeurotheranostics in Alzheimer's Disease: Current concepts and experimental strategies
Yanagisawa, D., Ohgita, T., Kawashima, H., Yoshikawa, H., Saito, H., Tooyama, I., & Takata, K. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109084 · Cited by 1
Emerging diagnostic biomarkers and therapeutic targets in Alzheimer's disease
Dineshbhai, T. K., Rafaliya, D., Singh, A., Maheshwari, S., Lalan, M. S., & Chakraborthy, G. S. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02341-z · Cited by 1
Popp, J., Georgescu, D., Bürge, M., Mundwiler, E., Bernasconi, L., & Felbecker, A. (2022) · JMIG · doi:10.53738/revmed.2022.18.808.2400 · Cited by 1
BIOMARCADORES SANGUÍNEOS APLICADOS AO DIAGNÓSTICO PRECOCE DA DOENÇA DE ALZHEIMER
Gomes, E. M. D. M., da Silva, A. A., & Guerra, B. S. (2023) · Editora e-Publicar eBooks · doi:10.47402/ed.ep.c2023423115655 · Cited by 1
Traits and Trammels of Tau Tracer Imaging
Villemagne, V. L., Lopresti, B. J., Doré, V., Minhas, D. S., Gogola, A., Nadkarni, N. K., Mason, N. S., Bourgeat, P., López, O. L., Ikonomović, M. D., et al. (2023) · Springer eBooks · doi:10.1007/978-3-031-35098-6_6 · Cited by 1
Biomarkers used in Alzheimer's disease diagnosis
Mishra, S. K., Singh, R., Chang, H., Obaid, A. A., & Singh, S. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15540-6.00013-6 · Cited by 1
Leclerc, H., Lee, A. K., Kunicki, Z. J., & Alber, J. (2024) · Journal of Alzheimer s Disease · doi:10.1177/13872877241283692 · Cited by 1
Fluid and Imaging Markers of Frontotemporal Lobar Degeneration
Prinse, F., Houwer, J. F. H. D., Dopper, E. G. P., & Seelaar, H. (2025) · Springer eBooks · doi:10.1007/978-3-031-80849-4_9 · Cited by 1
Bartesaghi, R., Chen, X., Johnstone, A. D., Das, U., & Mobley, W. C. (2025) · Springer eBooks · doi:10.1007/978-3-031-89307-0_19 · Cited by 1
Gonçalves, A. J., Alotaibi, M., Carlin, A., Chen, Y., Wong, C., Djoukhadar, I., Krokos, G., Jackson, A., Coope, D. J., & Asselin, M. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x211061050 · Cited by 1
Wojdała, A. L., Bellomo, G., Gaetani, L., Shan, D., Parnetti, L., & Chiasserini, D. (2023) · medRxiv · doi:10.1101/2023.06.08.23291128 · Cited by 1
Vrillon, A. (2022) · theses.fr (ABES) · doi:10.70675/58f64870z23eaz429bz9f78z6d92e769384b · Cited by 1
Exploratory Blood Biomarker Patterns in a Mixed Dementia CohortPreprint
Gezegen, H., Alaylıoğlu, M., Şahin, E., Swann, O., Veleva, E., Güven, G., Yaman, Ü., Salih, D. A. M., Bılgıç, B., Hanağası, H. A., et al. (2024) · medRxiv · doi:10.1101/2024.11.07.24316927 · Cited by 1
Self-citationTang, Z., Guo, M., Ding, Y., Wen, Y., Li, B., Xiao, Y., Ni, R., Guan, Z.-Z., & Qi, X. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.24.625068 · Cited by 1
Zhuang, X., Cordes, D., Bekris, L. M., Oh, E. C. T., & Bernick, C. B. (2025) · medRxiv · doi:10.1101/2025.09.19.25335803 · Cited by 1
Morgado, B. (2025) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-11551 · Cited by 1
Bergström, S. (2021) · KTH Publication Database DiVA (KTH Royal Institute of Technology) · Cited by 1
Rissardo, J. P., & Caprara, A. L. F. (2025) · Preprints.org · doi:10.20944/preprints202512.2722.v1 · Cited by 1
Plaska, C. R., Jacobs, T., Bruno, D., Lee, S. H., Imbimbo, B. P., Osorio, R., Benedet, A. L., Ashton, N. J., Zetterberg, H., Pomara, N., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.30.702902 · Cited by 1
Self-citationJacquemin, C. (2023) · theses.fr (ABES) · doi:10.70675/574d02aaz56daz485fz843dz68565d474db9 · Cited by 1
Recasens, B. B., Ortiz‐Romero, P., Lugo-Hernández, F., Vidal-Notari, S., Diego‐Osaba, M. D., Blasco‐Forniés, H., Jiménez‐Moyano, E., Trujillano, M. L., Torres‐Torronteras, J., del Campo, M., et al. (2026) · medRxiv · doi:10.64898/2026.07.03.26356752 · Cited by 1
Menopausal Hormone Therapy and Brain Health: Current Evidence, Knowledge Gaps, and Future DirectionsPreprint
Rabin, J. S., Alexander, M. W., Arvanitakis, Z., Baker, S. L., Barha, C. K., Buckley, R. F., Casaletto, K. B., Galea, L. A. M., Einstein, G., Kantarci, K., et al. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.7196839 · Cited by 1
Frisch, C., Baker, L., Srinivasan, G., Mintah, A. E., Leyasi, S., Pedroza, M., Galyon, B., & Brafman, D. A. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1856154
Astrocytic APOE3-Christchurch expression ameliorates brain amyloid-β pathology in 5xFAD mice
Raulin, A.-C., Alnobani, A., Rodriguez-Martinez, P., Lee, E., Linares, C., Yslas, A. R., Li, M., Ren, Y., Doss, S. V., Roy, B., et al. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-04002-9
A Tau Biomarker Is Detected in Blood Before the Clinical Onset of Alzheimer's Symptoms
Talan, J. (2021) · Neurology Today · doi:10.1097/01.nt.0000743532.27985.a4
Saunders, T. S., Heslegrave, A., King, D., Harris, S. E., Ritchie, C. W., Terrera, G. M., Deary, I. J., Cox, S. R., Zetterberg, H., & Spires‐Jones, T. L. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.24.469836
Self-citationRecent advances in blood and gut microbiota biomarkers for Alzheimer’s disease
Wu, S., Li, H., Tong, L., & Zhou, L. I. U. (2021) · Scientia Sinica Vitae · doi:10.1360/ssv-2021-0100
Turk, K. W., Geada, A., Alvarez, V. E., Xia, W., Cherry, J. D., Nicks, R., Meng, G., Daley, S. A., Tripodis, Y., Huber, B. R., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.051392
Metadata
- Authors
- Ashton, N. J., Pascoal, T. A., Karikari, T. K., Benedet, A. L., Lantero-Rodriguez, J., Brinkmalm, G., Snellman, A., Schöll, M., Troakes, C., Hye, A., Gauthier, S., Vanmechelen, E., Zetterberg, H., Rosa-Neto, P., & Blennow, K.
- Affiliations
- King's College London (GB)
- University of Pittsburgh (US)
- University of Gothenburg (SE)
- McGill University (CA)
- National Hospital for Neurology and Neurosurgery (GB)
- McGill University Research Centre for Studies in Aging (CA)
- ADx NeuroSciences (BE)
- Sahlgrenska University Hospital (SE)
- Corresponding author
- Ashton, Nicholas J.
- Blennow, Kaj
- ORCID
- Venue
- Acta Neuropathologica
- Published
- 2021-02-14
- Volume
- 141
- Issue
- 5
- Pages
- 709-724
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC8043944
- OpenAlex
- W3131174931
- Cited by
- 719
- References
- 66
- Citations by year
- 2026: 122 · 2025: 165 · 2024: 148 · 2023: 112 · 2022: 126 · 2021: 46
- FWCI
- 77.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Acta Neuropathologica (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Funders
- University of Gothenburg
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, tau phosphorylation, blood biomarkers, Simoa, amyloid PET, Braak staging, cognitive impairment, mild cognitive impairment, cerebrospinal fluid biomarkers, neurodegeneration, early detection of Alzheimer's disease, [18F]MK-6240
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Female, Humans, Male, Middle Aged, Phosphorylation, Biomarkers, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.